Search Site

Trends banner

ADNOC Drilling H1 revenue $2.37bn

The company posted a net profit of $692m.

Eni profit falls due to dip in oil prices

Q2 net profit fell by 18% to $637 million.

Emirates NBD H1 profit $3.40bn

Total income rose by 12 percent in the same period.

ADIB H1 pre-tax profit $1.08bn

Q2 pre-tax net profit increases by 14 percent.

AstraZeneca to invest $50bn in US

Bulk of funds to go into a Virginia manufacturing center.

Saudi Chemical, GlaxoSmithKline enter into $27m manufacturing deal

    • New partnership would help create more jobs for Saudis in the Kingdom’s pharmaceuticals sector

    • The partnership is in keeping with Saudi vision to diversify its economy away from oil

    Saudi Chemical Company Holding (SCCH) and GlaxoSmithKline have entered into a partnership to make pharmaceutical products in Saudi Arabia. SCCH unit AJA Pharmaceutical Industries have teamed up with GlaxoSmithKline Consumer Healthcare Saudi in a five-year production deal worth SR100 million ($27 million), the company said in a Saudi stock exchange filing on Thursday.

    Quoting SCCH Chief Executive Officer, Arab News reported that the new partnership would help create more jobs for Saudis in the Kingdom’s pharmaceuticals sector. “Our mission is to be the partner of choice,” said SCCH CEO Thamer Al-Muhid.

    Saudi Arabia aims to diversify its economy away from oil by adding more high value jobs at home and replacing imports with domestic manufacturing in key sectors such as pharmaceuticals.